

# Chemotherapy Sensitizes Colon Cancer Initiating Cells to V $\gamma$ 9V $\delta$ 2 T Cell-Mediated Cytotoxicity

Matilde Todaro<sup>1,2</sup>, Valentina Orlando<sup>2,3</sup>, Giuseppe Cicero<sup>1</sup>, Nadia Caccamo<sup>2,3</sup>, Serena Meraviglia<sup>3</sup>, Giorgio Stassi<sup>1</sup>, Francesco Dieli<sup>2,3\*</sup>

**1** Dipartimento di Discipline Chirurgiche ed Anatomiche, Università di Palermo, Palermo, Italy, **2** Biomedical Research Centre, Università di Palermo, Palermo, Italy,

**3** Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Università di Palermo, Palermo, Italy

## Abstract

Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5-fluorouracil and doxorubicin, sensitize colon CICs to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity. V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity was largely mediated by TRAIL interaction with DR5, following NKG2D-dependent recognition of colon CIC targets. We conclude that *in vivo* activation of V $\gamma$ 9V $\delta$ 2 T cells or adoptive administration of *ex-vivo* expanded V $\gamma$ 9V $\delta$ 2 T cells at suitable intervals after chemotherapy may substantially increase anti-tumor activities and represent a novel strategy for colon cancer immunotherapy.

**Citation:** Todaro M, Orlando V, Cicero G, Caccamo N, Meraviglia S, et al. (2013) Chemotherapy Sensitizes Colon Cancer Initiating Cells to V $\gamma$ 9V $\delta$ 2 T Cell-Mediated Cytotoxicity. PLoS ONE 8(6): e65145. doi:10.1371/journal.pone.0065145

**Editor:** Jacques Zimmer, Centre de Recherche Public de la Santé (CRP-Santé), Luxembourg

**Received:** March 5, 2013; **Accepted:** April 23, 2013; **Published:** June 6, 2013

**Copyright:** © 2013 Todaro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work has been supported by grants from the Italian Ministry for Instruction, University and Research (contract no. 2008L57JXW to FD), the Italian Ministry of Health (Progetto Ricerca Finalizzata 2007 “Stem cells in different pathological conditions: innovative therapeutical approaches” to FD), Istituto Superiore di Sanità Oncoproteomic Project 2007-527/B/3A/3 (to GS and FD) and the University of Palermo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors declare no financial or commercial conflict of interest. The corresponding author, Francesco Dieli, is an Academic Editor of PLOS ONE. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

\* E-mail: francesco.dieli@unipa.it

## Introduction

In recent years, novel insights in cancer research have suggested that the capacity to initiate and sustain tumor growth is a unique characteristic of a small subset of cancer cells with stemness properties within the tumor mass, called “cancer stem cells” (CSCs) or “cancer-initiating cells” (CICs) [1]. Chemotherapy remains the primary treatment choice for many advanced cancers and has cytotoxic anti-tumor activity through a range of mechanisms. However, most cancers are resistant to current therapies due to the slow-cycling CICs, the location of these cells within hypoxic niches [2,3], and because the malignant cells have the capacity to develop mechanisms to resist or escape the cytotoxic effects of chemotherapy [4], which include up-regulation of several ATP-binding cassette transporters, active DNA-repair capacity and over-expression of anti-apoptotic molecules that cause changes in the signalling pathways controlling proliferation, differentiation and apoptosis [5].

Several studies have demonstrated that treatment of tumor cells with chemotherapeutic drugs induces or increases their sensitivity to cytotoxicity by NK or T lymphocytes; thus, combinations of cellular immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of many forms of cancer [6].

V $\gamma$  $\delta$  T cells are of particular interest for use in such combined therapies due to their potent anti-tumor cytotoxicity and the

relative ease of generation *in vitro* [7]. Human  $\gamma\delta$  T cells can be divided into two main populations based upon  $\delta$  chain expression [8]:  $\gamma\delta$  T cells expressing the V $\delta$ 1 chain are most often found in mucosal tissues, where they are involved in maintaining epithelial tissue integrity in the face of damage, infection, or tumor transformation, while  $\gamma\delta$  T cells expressing the V $\delta$ 2 chain paired to the V $\gamma$ 9 chain (here and thereafter called V $\gamma$ 9V $\delta$ 2 T cells) predominate in the peripheral blood and secondary lymphoid organs [9]. While the ligand(s) recognized by V $\delta$ 1 cells remain unknown, V $\gamma$ 9V $\delta$ 2 T cells recognize non peptidic antigens by a MHC-unrestricted mechanism, an important feature which distinguishes them from  $\alpha\beta$  T cells [9]. Specifically, V $\gamma$ 9V $\delta$ 2 T cells recognize phosphoantigens that are produced through the isoprenoid biosynthesis pathways [10–12]. Phosphoantigens are not stimulatory at physiologic levels, but transformed and infected cells, produce increased levels of metabolic intermediates that are able to activate V $\gamma$ 9V $\delta$ 2 T cells [13–15]. Accordingly, V $\gamma$ 9V $\delta$ 2 T cells can also be activated, through an indirect mechanism, by aminobisphosphonates, a class of drugs used to treat certain bone diseases, that inhibit farnesyl pyrophosphate synthase, and cause accumulation of endogenous upstream metabolites such as isopentenylpyrophosphate (IPP) [16]. V $\gamma$ 9V $\delta$ 2 T cells may indirectly contribute to the immune defense against cancer cells, by producing cytokines typical of Th1, Th2 or Th17 cells [17–19], or cross-talking with dendritic cells [20], macrophages [21] and B cells [22–24]. Additionally, V $\gamma$ 9V $\delta$ 2 T cells perform direct potent

cytotoxic activity toward cancer cells, which is mediated in much the same manner as for CD8 T cells and NK cells, through perforin/granzyme, Fas/FasL, TNF/TNF-R and TRAIL-TRAIL-R pathways [10].

In this study, we have assessed the potential synergy of combining chemotherapy and V $\gamma$ 9V $\delta$ 2 T cell-mediated cytotoxicity for anti-tumor therapy. Specifically, as colon CICs are resistant to both chemotherapeutic drugs and to V $\gamma$ 9V $\delta$ 2 T cell-mediated cytotoxicity, we have determined whether chemotherapy can be used to sensitize colon CIC targets to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity, based on three lines of evidence: (1) pioneering work by Mattarollo and colleagues [25] has demonstrated high levels of cytotoxicity against solid tumor-derived cell lines with combination treatment utilizing V $\gamma$ 9V $\delta$ 2 T cells and chemotherapeutic agents; (2) IL-17-producing  $\gamma\delta$  T cells play a decisive role in chemotherapy-induced anti-cancer immune responses in the mouse [26]; (3) treatment of colon CICs with the bisphosphonate zoledronate enhances their sensitivity to V $\gamma$ 9V $\delta$ 2 T cell killing [27].

We show here that chemotherapeutic drugs currently used for treatment of colon cancer patients, 5-fluorouracil and doxorubicin, are capable to sensitize colon CICs to V $\gamma$ 9V $\delta$ 2 T cell-mediated killing and we demonstrate that the underlying mechanisms involve NKG2D and TRAIL.

## Results

### Resistance of Colon CICs to Chemotherapy

We have previously reported that colon cancer comprises a vast majority of differentiated cells and a small population of CICs that are responsible for tumor initiation and maintenance [28]. For this study purposes, we purified and propagated colon cancer spheres from surgical fragments of 5 patients with colon carcinoma. These cancer sphere lines were identified through the expression of CD133 and the epithelial specific antigen ESA, displayed adherence to the culture dishes in the presence of serum and subsequently differentiated into large, polygonal colon cells expressing colon epithelial markers, such as villin, suggesting that colon cancer spheres maintained the ability to *in vitro* differentiate in enterocyte-like cells. Most importantly, when injected subcutaneously into NOD/SCID mice, a low number of colon cancer spheres, but not sphere-derived differentiated cells, retained the capacity to form a tumor that closely resembled the human original tumor (**Supporting Figure S1**).

CICs are characterized by high resistance to drugs and general toxins which target rapidly proliferating cells and spare the slow dividing cells, due to an up-regulation of several ATP-binding cassette transporters, active DNA-repair capacity, over-expression of anti-apoptotic molecules that cause changes in the signalling pathways controlling proliferation, differentiation and apoptosis [5]. Accordingly, exposure of 5 different colon CIC lines (CIC#1 to CIC#5) to 5-FU (2.5 and 25  $\mu$ g/ml) (**Figure 1A**) or DXR (0.025 and 0.25  $\mu$ M) (**Figure 1B**) for 24–72 hrs had virtually no significant cytotoxic effect, as determined by PI staining. Highest doses of 5-FU (250  $\mu$ g/ml) and DXR (2.5  $\mu$ M) caused low, yet detectable cytotoxicity of CIC lines ranging from 15 $\pm$ 5% to 23 $\pm$ 6% (mean  $\pm$  SD). Conversely, 5-FU and DXR were fully capable of killing 3 differentiated colon cancer cell lines DLD-1, SW620 and SW403, and 2 differentiated cell lines (CDC#3 and CDC#4) obtained from two patients (P#3 and P#4) where form the CICs lines were also obtained, with a dose-dependent increase in cytotoxicity up to 85%. The viability of untreated cells was all over 90% (**Figures 1A and B**).

### Chemotherapy Sensitizes Colon CICs to V $\gamma$ 9V $\delta$ 2 T Cell Cytotoxicity

In analogy to their resistance to chemotherapy, the five tested colon CIC lines, were also resistant to V $\gamma$ 9V $\delta$ 2 T cell-mediated cytotoxicity, even when an E:T ratio of 50:1 was used (**Figure 2A**). The poor cytotoxic activity against colon CICs was not an intrinsic feature of the V $\gamma$ 9V $\delta$ 2 T cells, because the differentiated colon cancer cell lines DLD-1, SW620, SW403, CDC#3 and CDC#4 were efficiently killed by two V $\gamma$ 9V $\delta$ 2 T cell lines COLD2-1 and COLD2-2 obtained from two different colon cancer patients (P#3 and P#4) (**Figure 2A**), as well as V $\gamma$ 9V $\delta$ 2 T cell lines obtained from healthy subjects (data not shown). As a control, all the tested V $\gamma$ 9V $\delta$ 2 T cell lines failed to kill the normal colon cell line CCL-241 (**Figure 2A**).

In previous studies, we have demonstrated that zoledronate sensitizes colon cancer CICs to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity [27]. The capability of V $\gamma$ 9V $\delta$ 2 T cells to kill colon cancer CICs was then assessed after treatment of the targets with chemotherapy. Representative results obtained with three different CIC lines (CIC#2, CIC#4 and CIC#5) are shown in **Figure 2B**. V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity was enhanced in all cases by pretreatment of target CICs with chemotherapy. In detail, almost complete lysis of CIC lines resulted from the combination of the highest doses of 5-FU (250  $\mu$ g/ml) or DXR (2.5  $\mu$ M) and V $\gamma$ 9V $\delta$ 2 T cells, with cell death percentages over 90% at an E:T ratio of 20:1. Treatment of targets with lower doses chemotherapy (2.5 and 25  $\mu$ g/ml 5-FU and 0.025 and 0.25  $\mu$ M DXR) resulted in enhanced killing of CIC lines by V $\gamma$ 9V $\delta$ 2 T cells, indicating that chemotherapy and V $\gamma$ 9V $\delta$ 2 T cells have additive activity even when used at suboptimal doses.


### Chemotherapy Upregulates DR5 (TRAIL-R2) Death Receptor Expression on CICs

To decipher the molecular mechanisms behind chemotherapy-mediated sensitization of CICs to V $\gamma$ 9V $\delta$ 2 T cells cytotoxicity, we focused on expression of mRNA encoding for molecules known to be ligands for key activating receptors on V $\gamma$ 9V $\delta$ 2 T cells and death receptors, before and after exposure of CICs to chemotherapy agents. As shown in **Figure 3**, all of these molecules were constitutively expressed in CICs, although expression consistently varied amongst different CIC lines; however, no major differences were observed in all tested CIC lines for HLA-class I, ICAM-1, CD155, CD112, MICA/B and ULPBP1–4 expression before and after exposure to chemotherapy agents.

Expression of Fas (CD95), TNF-R1, DR4 (TRAIL-R1) and DR5 (TRAIL-R2) death receptors was increased in the majority of CIC lines following exposure to chemotherapeutic agents (**Figure 3**), but increased expression of Fas, TNF-R1 and DR4 did not attain statistical significance. The greatest and significant increase was only observed for DR5 expression after exposure of CICs to 5-FU and, although at a lesser extent, DXR (**Figure 3**). Upregulation of DR5 following 48 hrs exposure of colon CICs to chemotherapy was confirmed by flow cytometry upon staining with specific mAb (**Figure 4**).

### Killing of Chemotherapy-treated CICs by V $\gamma$ 9V $\delta$ 2 T Cells is Mediated by NKG2D and TRAIL

V $\gamma$ 9V $\delta$ 2 T cells exploit different pathways for killing of tumor cells that rely on secretion of proinflammatory cytokines and proapoptotic molecules or on cell contact-dependent lysis through NK-like or TCR-dependent interactions [9]. We assessed the mechanisms responsible for killing of chemotherapy-sensitized CICs by V $\gamma$ 9V $\delta$ 2 T cells, by individually blocking TCR or



**Figure 1. Cell cytotoxicity following treatment with 5-FU (A) or DXR (B).** Colon CICs, differentiated colon cancer cell lines DLD-1, SW620, SW403, CDC#3 and CDC#4 were treated with different concentrations of 5-FU or DXR for 48 hrs. Cytotoxicity (%  $\pm$  SD) was determined by the degree of reduction of viable cells with the ability to retain CFSE and exclude PI (CFSE<sup>high</sup> PI<sup>-</sup>). Shown is a representative experiment out of three. doi:10.1371/journal.pone.0065145.g001


NKG2D receptors. Cytotoxicity of chemotherapy-pretreated colon CIC lines by two different V $\gamma$ 9V $\delta$ 2 T cell lines was significantly inhibited by anti-NKG2D mAb, while the V $\gamma$ 9V $\delta$ 2 TCR seems to play a minor role as indicated by the failure of anti-CD3 and anti-pan  $\gamma\delta$  TCR mAbs to inhibit cytotoxicity (Figure 5). In addition, V $\gamma$ 9V $\delta$ 2 T cell killing of chemotherapy-sensitized targets was assessed in the presence of mevastatin, which inhibits 3-hydroxy-3-methylglutaryl-CoA and prevents zoledronate-mediated accumulation of endogenous phosphoantigens as IPP. Mevastatin failed to inhibit killing of all tested chemotherapy-pretreated colon CIC lines by two different allogeneic V $\gamma$ 9V $\delta$ 2 T cell lines (Figure 5), thus indicating that chemotherapy-induced sensitization of CICs to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity does not rely on production of mevalonate metabolites.

To further elucidate the mechanisms of killing of chemotherapy-sensitized colon CICs by V $\gamma$ 9V $\delta$ 2 T cells, we individually inhibited the granule exocytosis, TNF- $\alpha$ , TRAIL-, and FasL-mediated pathways. Killing-inhibition experiments revealed that V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity of chemotherapy-pretreated colon CIC targets was significantly inhibited by anti-DR5 mAb, whereas mAbs against DR4, TNF- $\alpha$ , and FasL, or treatment with CMA to block the granule-exocytosis pathway, all failed to inhibit. Figure 6 shows representative data with two V $\gamma$ 9V $\delta$ 2 T cell lines and the two colon CIC lines, CIC#2 and CIC#4.

## Discussion

It is now emerging that cancer is generated by a population of cells displaying stemness features, named cancer stem cells or cancer-initiating cells (CICs) [1,2]. These cells, which contribute only to a minor fraction of the total tumor mass, undergo long-term expansion with retention of their ability to reproduce the original tumor phenotype, thus providing evidence for self-renewal and tumor-initiating capacity [1,2]. The CIC population is more resistant than differentiated primary cells to conventional chemotherapy and radiotherapy and to putative innovative therapies such as those based on the use of TRAIL. This refractoriness has been attributed to the fact that CICs express multidrug resistance genes including high levels of anti-apoptotic proteins and ABC (ATP Binding Cassette) transporters which pump out the drugs, but also to the fact that chemotherapy targets dividing cells and consequently fails to kill the slow-cycling CICs [3–5].

Data from recent clinical studies have suggested that combining chemotherapy with immunotherapy has survival benefits than chemotherapy alone [6,29], as outlined for example by the combination of chemotherapy and monoclonal antibodies [30–32]. Moreover, it is known that chemotherapeutic drugs can sensitize tumor cells to cytotoxicity mediated by CD8, NKT or V $\gamma$ 9V $\delta$ 2 T cells [33] through several different mechanisms [34]. However, we recently found that colon CICs are resistant to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity, unless they are sensitized with zoledronate [35]: similarly, we have now tested the possibility



**Figure 2. Chemotherapy sensitizes resistant colon CICs to  $V\gamma 9V\delta 2$  cell-mediated cytotoxicity.** (A) Cytotoxicity percentage of 2 different  $V\gamma 9V\delta 2$  T cell lines, COLD2-1 and COLD2-2 obtained from 2 patients affected by colon cancer, against colon cancer sphere cells from 5 different patients (CIC#1 to CIC#5), differentiated colon cancer cell lines DLD-1, SW620, SW403, CDC#3 and CDC#4, and the normal colon cell line CCL-241, at an E:T ratio of 50:1. (B) Three different target colon CICs (CIC#2, CIC#4 and CIC#5) treated with or without either 5-FU (2.5 to 250  $\mu\text{g}/\text{ml}$ ) or DXR (0.025 to 2.5  $\mu\text{M}$ ) for 48 hrs were tested for their sensitivity to 2 different  $V\gamma 9V\delta 2$  T cell lines, COLD2-1 and COLD2-2 obtained from 2 patients affected by colon cancer and used at an E:T ratio of 20:1. Results indicate cytotoxicity of tumor targets following 6 hrs co-culture with  $V\gamma 9V\delta 2$  T cell lines. Data are mean percentage  $\pm$  SD of 5 different experiments, each carried out in triplicate. doi:10.1371/journal.pone.0065145.g002

that chemotherapeutic drugs currently used in the treatment of colon cancer might also sensitize colon CICs to  $V\gamma 9V\delta 2$  T cell killing.


Initial testing of cytotoxicity revealed that in analogy with our previously reported results [27], many colon CIC lines were resistant to the cytotoxic activity of  $V\gamma 9V\delta 2$  T cells, but pretreatment with low, sublethal concentrations of chemotherapeutic drugs 5-FU and DXR sensitizes CIC targets to  $V\gamma 9V\delta 2$  T cell killing, resulting in additive cytotoxicity activity.

$V\gamma 9V\delta 2$  T cells interact with and kill tumor targets through several different mechanisms including granule exocytosis, death receptor/ligands interactions with TNF, TRAIL and FasL, and TCR- or NKG2D-mediated recognition of phosphoantigens or stress-inducible molecules, respectively. All tested colon CIC lines constitutively expressed mRNA encoding for HLA-class I, ICAM-1, CD155, CD112, MICA/B, ULBP1-4, Fas (CD95), TNF-R1, DR4 (TRAIL-R1) and DR5 (TRAIL-R2) molecules on their

surface, but expression of all these molecules did not render CICs sensitive to  $V\gamma 9V\delta 2$  T cell killing. However, exposure of colon CICs to 5-FU and, although at a lesser extent DXR, significantly increased DR5 expression.

Several previously published reports in the literature have demonstrated that many chemotherapeutic drugs, including 5-FU and DXR, upregulate DR5 expression on tumor cell lines of distinct tissue origin [36–42]. However, this effect has been reported on differentiated cancer cells, while, to our knowledge, there is no evidence of similar DR5 upregulation on CICs. Whether or not chemotherapy-induced DR5 upregulation is restricted to colon CICs or is a general phenomenon observed on other CICs is actually under study.

Nonetheless, we found that  $V\gamma 9V\delta 2$  T cells exploited different mechanisms to kill CIC targets, which were strictly dependent on the way of target CICs sensitization. Regardless of whether chemotherapeutic drugs or zoledronate were used to sensitize



**Figure 3. Colon CICs constitutively express molecules involved in by  $V\gamma 9V\delta 2$  T cell-mediated cytotoxicity: effect of chemotherapy.** RT-PCR of the expression of mRNA encoding for different surface molecules in colon CICs treated with or without either 5-FU (25  $\mu\text{g}/\text{ml}$ ) or DXR (0.25  $\mu\text{M}$ ) for 48 hrs. Data represent the mean values  $\pm$  SD of 4 separate experiments, each performed with colon cancer spheres from 5 different patients (CIC#1 to CIC#5). doi:10.1371/journal.pone.0065145.g003

CICs,  $V\gamma 9V\delta 2$  T cells killing of these targets was TCR- or NKG2D-mediated: consistent with our previous report [27] chemotherapy-sensitized colon CICs were killed following NKG2D-mediated recognition and TRAIL/DR5 interaction, while both mechanisms were dispensable to the cytotoxicity of zoledronate-sensitized colon CICs, which were almost exclusively killed by TCR-mediated interaction and the perforin/granzyme pathway.

Previous studies have highlighted the importance of NKG2D-MICA/B interactions for tumour cell recognition and effective cytotoxic activity by  $V\gamma 9V\delta 2$  T cells [35–44]. The difference between NKG2D-mediated recognition of chemotherapy-sensitized colon CICs and TCR-mediated recognition of zoledronate-sensitized CIC targets cannot be explained differential expression of MICA/B or ULBPs since neither 5-FU nor DXR changed constitutive expression levels of these molecules. It is likely that phosphoantigens production/expression by colon CICs is very low, below the threshold required for efficient recognition by the reactive  $V\gamma 9V\delta 2$  TCR, hence target recognition only occurs through NKG2D: the finding that colon CICs become sensitive to  $V\gamma 9V\delta 2$  T cell cytotoxicity upon exposure to zoledronate [27],

which enhances phosphoantigen accumulation and production, supports this possibility.

We conclude that *in vivo* activation of  $V\gamma 9V\delta 2$  T cells or adoptive transfer of *ex vivo*-activated  $V\gamma 9V\delta 2$  T cells, together with or soon after administration of certain chemotherapeutic drugs may substantially increase their anti-tumor effects. Additional clinical studies are thus needed to assess the efficacy of this combinatory therapy, possibly including the novel  $\gamma\delta$  T cell-based immunotherapeutic approach that *ex-vivo* expansion of polyclonal  $\gamma\delta$  T cells followed by introduction of a CD19-specific chimeric antigen receptor render them bispecific and more efficient in killing of CD19<sup>+</sup> tumor cell lines *in vitro* and in xenografts [45].

## Materials and Methods


### Peripheral Blood and Colon Cancer Samples

Human peripheral blood mononuclear cells (PBMC) and colon cancer tissues were obtained in accordance with the ethical standards of the institutional committee of human experimentation from patients undergoing a colon resection for colon adenocarcinoma. Histological diagnosis was based on microscopic features of carcinoma cells determining the histological type and grade. PBMC were isolated from colon cancer patients by density gradient centrifugation using Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) and were cryopreserved in 80% RPMI 1640 (Life Technologies, Monza, Italy), 10% DMSO (Sigma, St. Louis, MO) and 10% heat-inactivated fetal calf serum (FCS, Life Technologies).


According to Italian rules (Article 13 of Legislative Decree no. 196/03), this study did not require authorisation by the local ethical committee. The study was performed in accordance to the principles of the Helsinki declaration and all individuals gave written informed consent to participate.

### Purification and Culture of CICs

Cancer tissues were extensively washed in saline buffer containing antibiotics and incubated overnight in DMEM/F12 (Life Technologies) containing penicillin (500 IU/ml), streptomycin (500  $\mu\text{g}/\text{ml}$ ) and amphotericin B (1.25  $\mu\text{g}/\text{ml}$ ) (Life Technol-



**Figure 4. Chemotherapy upregulates DR5 expression on colonic CICs.** Colon CICs were treated with medium, 5-FU (25  $\mu\text{g}/\text{ml}$ ) or DXR (0.25  $\mu\text{M}$ ) for 48 hrs, washed extensively and stained with anti-DR5 mAb. Flow cytometry histograms show DR5. Mean fluorescence intensity (MFI) for DR5 staining is indicated in the upper right corner of each panel. Dotted lines represent isotype control mAb, while grey filled histogram represent anti-DR5 mAb. doi:10.1371/journal.pone.0065145.g004



**Figure 5. Modulation of the cytotoxic activity of  $V\gamma9V\delta2$  T cells by blocking the TCR or NKG2D interactions.** The  $V\gamma9V\delta2$  T cell line COLD2-1 was cultured with two chemotherapy-treated colon CICs (CIC#3 and CIC#5) at an E:T ratio of 20:1, in the presence of blocking antibodies to the  $\gamma\delta$  TCR, CD3, NKG2D, or in the presence of mevastatin. Specific cytotoxicity levels achieved by the  $V\gamma9V\delta2$  T cell line COLD2-1 were  $65 \pm 11$  for CIC#3 and  $71 \pm 9$  for CIC#5. Data are mean  $\pm$  SD of two experiments carried out in triplicate. Percent inhibition with anti-NKG2D mAb was significantly different than values in all other groups (\* $p < 0.001$ ). doi:10.1371/journal.pone.0065145.g005

ogies). Enzymatic digestion was performed using collagenase (Life Technologies, 1.5 mg/ml) and hyaluronidase (Sigma, 20  $\mu$ g/ml) in DMEM containing antibiotics/antimycotics for 1 hour. Recovered cells were then cultured in serum-free medium (DMEM/F12) supplemented with 6 mg/ml Glucose, 1 mg/ml NaHCO<sub>3</sub>, 5 mM HEPES, 2 mM L-Glutamine, 4  $\mu$ g/ml Heparin, 4 mg/ml BSA, 10 ng/ml  $\beta$ FGF, 20 ng/ml EGF, 100  $\mu$ g/ml apotrasferrin, 25  $\mu$ g/ml insulin, 9.6  $\mu$ g/ml putrescin, 30 nM sodium selenite anhydrous and 20 nM progesterone (Sigma) to a final concentration of  $3 \times 10^5$  cells/ml. These culture conditions select for immature tumor cells that slowly proliferate, giving rise, within 2–3 months, to tumor cell aggregates, called “spheres”. Sphere-forming cells can be propagated by enzymatic dissociation of spheres (3 mM EDTA, 50 nM DTT in PBS), followed by replating of single cells and residual small cell aggregates in fresh serum-free medium [28,46,47].

Tumorigenicity was evaluated by subcutaneous implantation of either disaggregated colon cancer sphere cells or sphere-derived differentiated cells [27]. Differentiated colon cancer cells lines


DLD-1, SW620 and SW403 (American Type Culture Collection) were obtained from Dr. Ruggero De Maria (“Regina Elena” National Cancer Institute, Rome, Italy) and were maintained in DMEM containing antibiotics and 10% FCS. All cell cultures were carried out at 37°C in a 5% CO<sub>2</sub> humidified incubator.

#### Anti-tumor Agents, Antibodies and Reagents

The chemotherapeutic agents 5-fluorouracil (5-FU) and doxorubicin (DXR) were obtained from Sigma, through the pharmacy of the University Hospital. Drugs were diluted in DMSO and diluted to the required concentrations in PBS prior to use.

The following unconjugated, FITC-, PE-, PE-Cy5- or APC-conjugated monoclonal antibodies (mAbs) were used: anti-TCR V $\delta$ 2 (B6, BD Biosciences, San José, CA), anti-NKG2D (1D11, eBioscience, San Diego, CA), anti-CD95L (2C101, Vinci Biochem, Firenze, Italy), anti-MICA/B (6D4, BD Biosciences).

Additionally, the following purified mAbs were also used: anti-CD3 (blocking, MEM-57), anti-HLA Class I monomorphic (MEM-147) from Prof. Vaclav Horejsi (Institute of Molecular



**Figure 6. Modulation of the cytotoxic activity of  $V\gamma9V\delta2$  T cells by blocking death receptors interactions.** The  $V\gamma9V\delta2$  T cell line COLD2-1 was cultured with two chemotherapy-treated colon CICs (CIC#3 and CIC#5) at an E:T ratio of 20:1, in the presence of blocking antibodies to TNF- $\alpha$ , FasL (CD95L), TRAIL receptors R1 (DR4) or R2 (DR5), or concanamycin A (CMA). Specific cytotoxicity levels achieved by the  $V\gamma9V\delta2$  T cell line COLD2-1 were  $61 \pm 7$  for CIC#3 and  $65 \pm 12$  for CIC#5. Data are mean  $\pm$  SD of experiments carried out in triplicate. Percent inhibition with anti-DR5 and anti-TRAIL mAbs were significantly different than values in all other groups (\* $p < 0.001$ ). doi:10.1371/journal.pone.0065145.g006

Genetics, Prague, Czech republic), anti-TCR pan  $\gamma\delta$  (IMMU510, a gift of Dr. Marc Bonneville, Institut de Biologie, Nantes, France), anti-TNF- $\alpha$  (Infliximab, a gift of Prof. Giovanni Triolo, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy), anti-TRAIL receptors TRAIL-R1(DR4), TRAIL-R2 (DR5), TRAIL-R3 (LIT, DcR1) and TRAIL-R4 (TRUNDD, DcR2) all provided by Dr. Henning Walczak (Tumor Immunology Unit, Division of Medicine, Imperial College, London, UK).

Concanamycin A (CMA) and mevastatin were purchased from Sigma, while zoledronate was from Novartis Pharma, Basel, Switzerland.

### Generation of Polyclonal V $\gamma$ 9V $\delta$ 2 T Cell Lines

Polyclonal V $\gamma$ 9V $\delta$ 2 T cell lines were generated by first enriching PBMC using a  $\gamma\delta$  T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), followed by sorting single V $\gamma$ 9V $\delta$ 2 T cells through a FACSAria (BD Biosciences) with specific mAbs. Cells ( $2 \times 10^3$ ) were then cultured into each well of round-bottom, 96-well plates containing  $2 \times 10^4$  irradiated (40 Gy) allogeneic PBMC,  $2 \times 10^3$  irradiated (70 Gy) EBV-transformed allogeneic B cells, 0.5  $\mu$ g/ml PHA (Sigma), and 200 U/ml recombinant interleukin 2 (Proleukin, Novartis Pharma). Growing lines were expanded in 200 U/ml IL-2 and restimulated every 2 weeks. Usually, cells were collected after 4–6 weeks of culture to be used for functional assays *in vitro*.

### Cytotoxic Assay

Target colon CIC ( $10^5$  cells/ml) were pre-treated with 5-FU (2.5–250  $\mu$ g/ml), DXR (0.025–2.5  $\mu$ M) or zoledronate (0.5  $\mu$ M) for 24, 48 or 72 hrs. Cells were extensively washed in PBS and stained with CFSE (Merck, Milano, Italy) as follows: 50  $\mu$ l of CFSE were added to 1 ml of target sphere cell suspension ( $5 \times 10^5$  cells/ml) in PBS to obtain the final concentration of 2.5  $\mu$ M CFSE. The cells were incubated for 10 minutes at 37°C and gently mixed every 5 min. At the end of incubation, 1 ml of FBS was added to the cell suspension to stop the staining reaction and the cells were centrifuged at 600 g for 5 min at room temperature, washed twice with cold PBS and resuspended in serum-free medium.

V $\gamma$ 9V $\delta$ 2 T cell lines were resuspended at the final concentrations of  $10^6$  and  $2.5 \times 10^6$  cells/ml, were added to CFSE-stained target colon CICs ( $1 \times 10^5$ ) and co-cultures were maintained for 6 hrs at 37°C in presence of 5% of CO<sub>2</sub>. At the end of the incubation period, the cells were washed with PBS and stained with 20  $\mu$ l of Propidium Iodide (PI, Sigma, 1  $\mu$ g/ml) for 10–15 min in ice. Finally 100  $\mu$ l of cold PBS were added before acquisition on a FACSCalibur cytometer (BD Biosciences). The calculation of cytolytic activity was based on the degree of reduction of viable target cells with the ability to retain CFSE and exclude PI (CFSE<sup>high</sup> PI<sup>-</sup>), according to reference [27].

Blocking agents were used to evaluate the mechanisms of V $\gamma$ 9V $\delta$ 2 T cell-mediated cytotoxicity of colon CICs. To evaluate the contribution of mevalonate metabolites tumor target cells were treated with mevastatin (25  $\mu$ M for 2 h) a selective upstream inhibitor of the mevalonate pathway. After this incubation period, target cells were washed, and V $\gamma$ 9V $\delta$ 2 T cells added in the

presence of 25  $\mu$ M mevastatin, to maintain a constant concentration of this drug during incubation because its effect is rapidly reversible [27]. To inhibit perforin-mediated cytotoxicity, V $\gamma$ 9V $\delta$ 2 T cells were incubated with concanamycin A (CMA, 15 nM) for 30 min at 37°C before co-culture with target CICs, without further washing [27]. To block the relevant cytotoxic pathways, specific or isotype-control mAbs were used at 10  $\mu$ g/ml final concentration just before co-incubation assay [27].

### Real-time Quantitative RT-PCR

Total RNA was extracted with the ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems through Life Technologies) according to the manufacturer's instructions. Random hexamers and an MMLV Reverse Transcriptase kit (Stratagene, La Jolla, CA) were used for cDNA synthesis. Transcripts were quantified by real-time quantitative PCR on an ABI PRISM 7700 Sequence Detector (Applied Biosystems) with Applied Biosystems pre-designed TaqMan Gene Expression Assays and reagents according to the manufacturer's instructions. The following probes were used (identified by Applied Biosystems assay identification number): HLA-A, Hs01058806\_g1; HLA-B, Hs00818803\_g1; HLA-C, Hs00740298\_g1; ICAM-1, Mm00516023\_m1; CD155, Hs00197846\_m1; CD112, Hs01071562\_m1; MICA, Hs00741286\_m1; MICB, Hs00792952\_m1; ULBP-1, Mm01180648\_m1; ULBP-2, Hs00607609\_mH; ULBP-3, Hs00225909\_m1; Fas (CD95), Hs00236330\_m1; TNF-R1, Mm00441883\_g1; DR4 (TRAIL-R1), Hs00269492\_m1; DR5 (TRAIL-R2), Hs00366278\_m1. For each sample, mRNA abundance was normalized to the amount of 18S rRNA.

### Statistics

The two-tailed Student's *t* test was used to compare significance of differences between groups. All values are expressed as mean  $\pm$  standard deviation (SD).

### Supporting Information

**Figure S1 A low number of colon CIC spheres retain the capacity to form a tumor when injected s.c. into immunodeficient mice.** Subcutaneous tumor growth in NOD/SCID mice 10 weeks after injection of 2000 disaggregated cells from colon cancer spheres. One representative experiment of two performed with cells from different donors is shown. (TIF)

### Acknowledgments

We thank Ruggero De Maria, Vaclav Horejsi, Marc Bonneville, Giovanni Triolo and Henning Walczak for providing us with the cell lines and reagents.

### Author Contributions

Conceived and designed the experiments: GS FD. Performed the experiments: MT VO NC SM. Analyzed the data: GC GS FD. Contributed reagents/materials/analysis tools: GS FD. Wrote the paper: GS FD.

### References

- Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP (2008) Cancer stem cells old concepts, new insights. *Cell Death Differ* 15: 947–958.
- Koch U, Krause M, Baumann M (2010) Cancer stem cells at the crossroads of current cancer therapy failures—radiation oncology perspective. *Semin Cancer Biol* 20: 116–124.
- Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. *Nat Rev Cancer* 8: 545–554.
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. *N Engl J Med* 319: 525–532.
- Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. *Nat Rev Cancer* 5: 275–284.
- Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, et al. (2012) Immunotherapy of cancer in 2012. *CA Cancer J Clin* 62: 309–335.

7. Hammami D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L (2012) Harnessing  $\gamma\delta$  T cells in anticancer immunotherapy. *Trends Immunol* 33: 199–206.
8. Groh V, Porcelli S, Fabbri M, Lanier LL, Picker IJ, et al. (1989) Human lymphocytes bearing T cell receptor  $\gamma/\delta$  are phenotypically diverse and evenly distributed throughout the lymphoid system. *J Exp Med* 169: 1277–1294.
9. Bonneville M, O'Brien RL, Born WK (2010)  $\gamma\delta$  T cell effector functions: a blend of innate programming and acquired plasticity. *Nat Rev Immunol* 10: 467–478.
10. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human  $\gamma\delta$  T cells by nonpeptidic mycobacterial ligands. *Science* 264: 267–270.
11. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, et al. (2003) Microbial isoprenoid biosynthesis and human  $\gamma\delta$  T cell activation. *FEBS Lett* 544: 4–10.
12. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human  $\gamma\delta$  T cells. *Nature* 375: 155–158.
13. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, et al. (2003) Human T cell receptor  $\gamma\delta$  cells recognize endogenous mevalonate metabolites in tumor cells. *J Exp Med* 197: 163–168.
14. Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, et al. (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human  $\gamma\delta$  TCR cells. *Eur J Immunol* 38: 2200–2220.
15. Sireci G, Espinosa E, Di Sano C, Salerno A, Fournié JJ, et al. (2001) Differential activation of human  $\gamma\delta$  T cells by nonpeptide phosphoantigens. *Eur J Immunol* 31: 1628–1634.
16. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, et al. (2007) Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. *Proc Natl Acad Sci USA* 104: 10022–10027.
17. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, et al. (2007) Distinct cytokine-driven responses of activated blood  $\gamma\delta$  T cells: insights into unconventional T cell pleiotropy. *J Immunol* 178: 4304–4314.
18. Wesch D, Glatzel A, Kabelitz D (2001) Differentiation of resting human peripheral blood  $\gamma\delta$  T cells toward Th1- or Th2-phenotype. *Cell Immunol* 212: 110–117.
19. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, et al. (2011) Differentiation, phenotype and function of interleukin-17-producing human V $\gamma$ 9V $\delta$ 2 T cells. *Blood* 118: 129–138.
20. Meraviglia S, Caccamo N, Salerno A, Sireci G, Dieli F (2010) Partial and ineffective activation of V $\gamma$ 9V $\delta$ 2 T cells by Mycobacterium tuberculosis-infected dendritic cells. *J Immunol* 185: 1770–1776.
21. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, et al. (2009) A rapid crosstalk of human  $\gamma\delta$  T cells and monocytes drives the acute inflammation in bacterial infections. *PLoS Pathog* 5: e1000308.
22. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, et al. (2006) CXCR5 identifies a subset of V $\gamma$ 9V $\delta$ 2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. *J Immunol* 177: 5290–5295.
23. Bansal RR, Mackay CR, Moser B, Eberl M (2012) IL-21 enhances the potential of human  $\gamma\delta$  T cells to provide B-cell help. *Eur J Immunol* 42: 110–119.
24. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, et al. (2012) IL-21 regulates the differentiation of a human  $\gamma\delta$  T cell subset equipped with B cell helper activity. *PLoS One* 7: e41940.
25. Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2007) Chemotherapy and zoledronate sensitize solid tumour cells to V $\gamma$ 9V $\delta$ 2 T cell cytotoxicity. *Cancer Immunol Immunother* 56: 1285–1297.
26. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, et al. (2011) Contribution of IL-17-producing  $\gamma\delta$  T cells to the efficacy of anticancer chemotherapy. *J Exp Med* 208: 491–503.
27. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, et al. (2009) Efficient killing of human colon cancer stem cells by  $\gamma\delta$  T lymphocytes. *J Immunol* 182: 7287–7296.
28. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 1: 389–402.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 313: 1960–1964.
30. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, et al. (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. *J Clin Oncol* 23: 4110–4116.
31. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, et al. (2005) Sequential application of chemotherapy and monoclonal CD20 antibody: successful treatment of advanced composite-lymphoma. *Leukemia Lymphoma* 46: 285–288.
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 344: 783–792.
33. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy: a practical partnership. *Nat Rev Cancer* 5: 397–405.
34. Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V $\alpha$ 24<sup>+</sup> NKT cell-mediated cytotoxicity. *Int J Cancer* 119: 1630–1637.
35. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, et al. (2005) V $\gamma$ 9V $\delta$ 2 T cell response to colon carcinoma cells. *J Immunol* 175: 5481–5488.
36. Tong HX, Lu CW, Wang QS, Ma LY (2011) Combination of IFN $\gamma$  and chemotherapeutic agents increase TRAIL sensitivity of neuroblastoma cell lines. *Eur J Pediatr Surg* 21: 304–309.
37. Kang J, Bu J, Hao Y, Chen F (2005) Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. *Prostate Cancer Prostatic Dis* 8: 274–279.
38. Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y (2003) TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. *Pediatr Res* 54: 709–717.
39. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, et al. (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. *Int J Cancer* 99: 491–504.
40. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, et al. (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo2L-induced apoptosis of human acute leukemia cells. *Blood* 96: 3900–3906.
41. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y (2007) Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. *Cancer Sci* 98: 1969–1976.
42. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. *Cancer Res* 59: 734–741.
43. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived  $\gamma\delta$  T cells of MICA and MICB. *Proc Natl Acad Sci USA* 96: 6879–6884.
44. Wrobel P, Shojaci H, Schittek B, Gieseler F, Wollenberg B, et al. (2007) Lysis of a broad range of epithelial tumour cells by human  $\gamma\delta$  T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. *Scand J Immunol* 66: 320–328.
45. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, et al. (2013) Bispecific T-cells expressing polyclonal repertoire of endogenous  $\gamma\delta$  T-cell receptors and introduced CD19-specific chimeric antigen receptor. *Mol Ther* 21: 638–647.
46. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 64: 7011–7021.
47. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, et al. (2010) Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. *Cancer Res* 70: 7500–7513.